Area of research
Pulmonary and Respiratory Medicine · Physiology
Research interest
Research interests include Asthma and respiratory diseases, Chronic Obstructive Pulmonary Disease (COPD) Research, IL-33, ST2, and ILC Pathways, and Respiratory and Cough-Related Research.
Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging in patients with type 2 asthma (VESTIGE): a randomised, double-blind, placebo-controlled, phase 4 trial
Current Smoker: A Clinical Chronic Obstructive Pulmonary Disease Phenotype Affecting Disease Progression and Response to Therapy
Effect of dupilumab on mucus burden in patients with moderate-to-severe asthma: the VESTIGE trial
Le dupilumab réduit l’obstruction et le volume du mucus : essai de phase 4 VESTIGE
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD
Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma
Chronic Obstructive Pulmonary Disease Exacerbations Increase the Risk of Subsequent Cardiovascular Events: A Longitudinal Analysis of the COPDGene Study
The Emerging Role of Alarmin-Targeting Biologics in the Treatment of Patients With COPD
Real-world effectiveness of dupilumab versus benralizumab and mepolizumab
The Effect of Chronic Altitude Exposure on Chronic Obstructive Pulmonary Disease Outcomes in the SPIROMICS Cohort: An Observational Cohort Study
Evaluating the Effect of Dupilumab on Type 2 Airway Inflammation and Mucus Plugging in Patients with Uncontrolled Moderate-To-Severe Asthma: the VESTIGE Trial
Long-Term Dupilumab Efficacy on Severe Exacerbations and Lung Function in Patients with Type 2 Asthma
Dupilumab reduces mucus plugging and volume: phase 4 VESTIGE trial
Effect of Dupilumab Treatment on Mucus Plugging and Mucus Volume in Type 2 Asthma: The Phase 4 VESTIGE Trial
Early treatment response to dupilumab on airway inflammation, airway dynamics, and mucus plugging in VESTIGE
Évaluation de l’effet du dupilumab sur l’inflammation de type 2 des voies respiratoires et le bouchon de mucus chez les patients souffrant d’asthme modéré à sévère non contrôlé : l’essai VESTIGE
Dupilumab-treated patients with moderate-to-severe asthma are more likely to meet clinical remission criteria: results from the VESTIGE trial
Targeting Type 2 Inflammation and Epithelial Alarmins in Chronic Obstructive Pulmonary Disease: A Biologics Outlook
Real-world effectiveness of dupilumab in patients with asthma
Prevalence of abnormal spirometry in individuals with a smoking history and no known obstructive lung disease
Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
Dupilumab Reduces Exacerbations And Improves Lung Function Regardless Of Prior Asthma Exacerbation Status: LIBERTY ASTHMA TRAVERSE Open-Label Extension Study
Dupilumab improves exacerbations and lung function irrespective of prior asthma exacerbations: TRAVERSE
S118 Dupilumab efficacy is not affected by prior asthma exacerbation status in LIBERTY ASTHMA TRAVERSE open-label extension study
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction
Pulmonary Arterial Pruning and Longitudinal Change in Percent Emphysema and Lung Function
Emphysema Progression and Lung Function Decline Among Angiotensin Converting Enzyme Inhibitors and Angiotensin-Receptor Blockade Users in the COPDGene Cohort
COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease
Causes and Predictors of Death in Smokers with and Without COPD: An Analysis of the COPDGene Cohort
Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene® Cohort